Author | Sumanta Kumar Pal, MD | OncLive

Author | Sumanta Kumar Pal, MD

Articles

Dr. Pal on the Rationale for the TIVO-3 Trial With Tivozanib in Advanced RCC

September 15, 2020

Sumanta K. Pal, MD, discusses the rationale behind the phase 3 TIVO-3 trial with tivozanib in advanced renal cell carcinoma.

Dr. Pal on the Benefit of Tivozanib in Later-Line Settings for Refractory RCC

September 10, 2020

Sumanta K. Pal, MD, discusses the benefit of tivozanib in later-line setting treatment settings for patients with refractory renal cell carcinoma.

Dr. Pal on the Background of the COSMIC-021 Trial in ​Urothelial Cancer

June 24, 2020

Sumanta K. Pal, MD, discusses the background of the COSMIC-021 trial in urothelial cancer.

Dr. Pal on the Potential Use of PARP Inhibitors in RCC

February 11, 2020

Sumanta Kumar Pal, MD, discusses the potential use of PARP inhibitors in renal cell carcinoma.

x